Unknown

Dataset Information

0

Evaluating the effect of therapeutic stem cells on TRAIL resistant and sensitive medulloblastomas.


ABSTRACT: Mesenchymal stem cells (MSC) are emerging as novel cell-based delivery agents; however, a thorough investigation addressing their therapeutic potential in medulloblastomas (MB) has not been explored to date. In this study, we engineered human MSC to express a potent and secretable variant of a tumor specific agent, tumor necrosis factor-apoptosis-inducing ligand (S-TRAIL) and assessed the ability of MSC-S-TRAIL mediated MB killing alone or in combination with a small molecule inhibitor of histone-deacetylase, MS-275, in TRAIL-sensitive and -resistant MB in vitro and in vivo. We show that TRAIL sensitivity/resistance correlates with the expression of its cognate death receptor (DR)5 and MSC-S-TRAIL induces caspase-3 mediated apoptosis in TRAIL-sensitive MB lines. In TRAIL-resistant MB, we show upregulation of DR4/5 levels when pre-treated with MS-275 and a subsequent sensitization to MSC-S-TRAIL mediated apoptosis. Using intracranially implanted MB and MSC lines engineered with different combinations of fluorescent and bioluminescent proteins, we show that MSC-S-TRAIL has significant anti-tumor effects in mice bearing TRAIL-sensitive and MS-275 pre-treated TRAIL-resistant MBs. To our knowledge, this is the first study that explores the use of human MSC as MB-targeting therapeutic-vehicles in vivo in TRAIL-sensitive and resistant tumors, and has implications for developing effective therapies for patients with medulloblastomas.

SUBMITTER: Nesterenko I 

PROVIDER: S-EPMC3492275 | biostudies-literature | 2012

REPOSITORIES: biostudies-literature

altmetric image

Publications

Evaluating the effect of therapeutic stem cells on TRAIL resistant and sensitive medulloblastomas.

Nesterenko Irina I   Wanningen Simone S   Bagci-Onder Tugba T   Anderegg Maarten M   Shah Khalid K  

PloS one 20121107 11


Mesenchymal stem cells (MSC) are emerging as novel cell-based delivery agents; however, a thorough investigation addressing their therapeutic potential in medulloblastomas (MB) has not been explored to date. In this study, we engineered human MSC to express a potent and secretable variant of a tumor specific agent, tumor necrosis factor-apoptosis-inducing ligand (S-TRAIL) and assessed the ability of MSC-S-TRAIL mediated MB killing alone or in combination with a small molecule inhibitor of histon  ...[more]

Similar Datasets

2015-10-20 | GSE74130 | GEO
| S-ECPF-MEXP-247 | biostudies-other
| S-EPMC4515056 | biostudies-literature
2014-09-01 | GSE55859 | GEO
2014-09-01 | GSE55821 | GEO
2006-01-01 | E-MEXP-247 | biostudies-arrayexpress
2014-09-01 | E-GEOD-55859 | biostudies-arrayexpress
2014-09-01 | E-GEOD-55821 | biostudies-arrayexpress
2020-05-24 | E-MTAB-9151 | biostudies-arrayexpress
| S-EPMC8657692 | biostudies-literature